Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer
Kevin Kalinsky, Katherine D Crew, Susan Refice, Tong Xiao, Antai Wang, Sheldon M Feldman, Bret Taback, Aqeel Ahmad, Serge Cremers, Hanina Hibshoosh, Matthew Maurer, Dawn L Hershman, Kevin Kalinsky, Katherine D Crew, Susan Refice, Tong Xiao, Antai Wang, Sheldon M Feldman, Bret Taback, Aqeel Ahmad, Serge Cremers, Hanina Hibshoosh, Matthew Maurer, Dawn L Hershman
Abstract
Introduction: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients.
Methods: Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage.
Results: There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin.
Conclusion: Despite no proliferation changes, we observed reductions in other relevant biomarkers.
Trial registration: ClinicalTrials.gov NCT00930579.
Conflict of interest statement
DECLARATION OF INTEREST
The authors declare that they have no conflict of interest. The authors alone are responsible for the content and writing of the article.
Figures
Source: PubMed